JP7506060B2 - 検出限界ベースの品質管理メトリック - Google Patents
検出限界ベースの品質管理メトリック Download PDFInfo
- Publication number
- JP7506060B2 JP7506060B2 JP2021517942A JP2021517942A JP7506060B2 JP 7506060 B2 JP7506060 B2 JP 7506060B2 JP 2021517942 A JP2021517942 A JP 2021517942A JP 2021517942 A JP2021517942 A JP 2021517942A JP 7506060 B2 JP7506060 B2 JP 7506060B2
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- fetal fraction
- sample
- coverage
- chromosome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims description 80
- 238000003908 quality control method Methods 0.000 title description 32
- 230000001605 fetal effect Effects 0.000 claims description 452
- 238000000034 method Methods 0.000 claims description 326
- 238000012360 testing method Methods 0.000 claims description 261
- 150000007523 nucleic acids Chemical group 0.000 claims description 204
- 238000012163 sequencing technique Methods 0.000 claims description 178
- 238000009826 distribution Methods 0.000 claims description 68
- 238000012549 training Methods 0.000 claims description 56
- 230000007717 exclusion Effects 0.000 claims description 53
- 238000012545 processing Methods 0.000 claims description 42
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- 210000003754 fetus Anatomy 0.000 claims description 21
- 238000000126 in silico method Methods 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000015654 memory Effects 0.000 claims description 6
- 239000000523 sample Substances 0.000 description 496
- 210000000349 chromosome Anatomy 0.000 description 352
- 102000039446 nucleic acids Human genes 0.000 description 129
- 108020004707 nucleic acids Proteins 0.000 description 129
- 239000012634 fragment Substances 0.000 description 123
- 208000036878 aneuploidy Diseases 0.000 description 120
- 102000053602 DNA Human genes 0.000 description 103
- 108020004414 DNA Proteins 0.000 description 103
- 230000008569 process Effects 0.000 description 90
- 231100001075 aneuploidy Toxicity 0.000 description 73
- 230000008774 maternal effect Effects 0.000 description 71
- 239000003550 marker Substances 0.000 description 64
- 230000002759 chromosomal effect Effects 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 51
- 238000004458 analytical method Methods 0.000 description 49
- 230000003322 aneuploid effect Effects 0.000 description 47
- 239000000203 mixture Substances 0.000 description 33
- 210000002381 plasma Anatomy 0.000 description 29
- 238000010606 normalization Methods 0.000 description 27
- 239000012472 biological sample Substances 0.000 description 25
- 238000003745 diagnosis Methods 0.000 description 24
- 102000040430 polynucleotide Human genes 0.000 description 24
- 108091033319 polynucleotide Proteins 0.000 description 24
- 239000002157 polynucleotide Substances 0.000 description 24
- 230000006870 function Effects 0.000 description 23
- 230000035945 sensitivity Effects 0.000 description 23
- 230000003321 amplification Effects 0.000 description 22
- 238000003199 nucleic acid amplification method Methods 0.000 description 22
- 230000000875 corresponding effect Effects 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 201000010374 Down Syndrome Diseases 0.000 description 19
- 206010044688 Trisomy 21 Diseases 0.000 description 19
- 208000037280 Trisomy Diseases 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000007481 next generation sequencing Methods 0.000 description 16
- 230000036961 partial effect Effects 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 210000002593 Y chromosome Anatomy 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 238000007796 conventional method Methods 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 238000001574 biopsy Methods 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 238000013467 fragmentation Methods 0.000 description 11
- 238000006062 fragmentation reaction Methods 0.000 description 11
- 239000013060 biological fluid Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 229920002477 rna polymer Polymers 0.000 description 10
- 210000001766 X chromosome Anatomy 0.000 description 9
- 238000004590 computer program Methods 0.000 description 9
- 238000013507 mapping Methods 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000000513 principal component analysis Methods 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 201000006360 Edwards syndrome Diseases 0.000 description 7
- 108091093037 Peptide nucleic acid Proteins 0.000 description 7
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000000873 masking effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 206010053884 trisomy 18 Diseases 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 238000012369 In process control Methods 0.000 description 6
- 201000009928 Patau syndrome Diseases 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 206010044686 Trisomy 13 Diseases 0.000 description 6
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000009795 derivation Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000013610 patient sample Substances 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000016679 Monosomy X Diseases 0.000 description 5
- 208000026928 Turner syndrome Diseases 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 108091092356 cellular DNA Proteins 0.000 description 5
- -1 cfDNA Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 230000002559 cytogenic effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000003917 human chromosome Anatomy 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000003793 prenatal diagnosis Methods 0.000 description 5
- 238000012797 qualification Methods 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 210000003765 sex chromosome Anatomy 0.000 description 5
- 210000004243 sweat Anatomy 0.000 description 5
- 210000001138 tear Anatomy 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000009223 counseling Methods 0.000 description 4
- 210000004544 dc2 Anatomy 0.000 description 4
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000004190 ion pair chromatography Methods 0.000 description 4
- 230000011987 methylation Effects 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000003567 ascitic fluid Anatomy 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 238000013412 genome amplification Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000012886 linear function Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000013178 mathematical model Methods 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 208000030454 monosomy Diseases 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000009598 prenatal testing Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000020584 Polyploidy Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000002669 amniocentesis Methods 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000003066 decision tree Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010448 genetic screening Methods 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010965 in-process control Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 150000002972 pentoses Chemical group 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000004713 phosphodiesters Chemical group 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000007841 sequencing by ligation Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 208000026485 trisomy X Diseases 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 208000026817 47,XYY syndrome Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 208000031639 Chromosome Deletion Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 108091093094 Glycol nucleic acid Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101000757182 Saccharomyces cerevisiae Glucoamylase S2 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101100388071 Thermococcus sp. (strain GE8) pol gene Proteins 0.000 description 1
- 108091046915 Threose nucleic acid Proteins 0.000 description 1
- 206010053871 Trisomy 8 Diseases 0.000 description 1
- 206010071547 Trisomy 9 Diseases 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019689 luncheon sausage Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000034352 partial segmental duplication Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 108010062513 snake venom phosphodiesterase I Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 206010044689 trisomy 22 Diseases 0.000 description 1
- 208000034298 trisomy chromosome 8 Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/20—Sequence assembly
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
Landscapes
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- General Health & Medical Sciences (AREA)
- Theoretical Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Artificial Intelligence (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856651P | 2019-06-03 | 2019-06-03 | |
| US62/856,651 | 2019-06-03 | ||
| PCT/US2020/035787 WO2020247411A1 (en) | 2019-06-03 | 2020-06-02 | Limit of detection based quality control metric |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022534634A JP2022534634A (ja) | 2022-08-03 |
| JP2022534634A5 JP2022534634A5 (https=) | 2022-10-26 |
| JP7506060B2 true JP7506060B2 (ja) | 2024-06-25 |
Family
ID=71842782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517942A Active JP7506060B2 (ja) | 2019-06-03 | 2020-06-02 | 検出限界ベースの品質管理メトリック |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12260935B2 (https=) |
| EP (1) | EP3977459A1 (https=) |
| JP (1) | JP7506060B2 (https=) |
| KR (1) | KR20220013349A (https=) |
| CN (1) | CN112823391B (https=) |
| AU (1) | AU2020286376A1 (https=) |
| CA (1) | CA3115513A1 (https=) |
| WO (1) | WO2020247411A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023552015A (ja) * | 2020-12-02 | 2023-12-14 | イルミナ ソフトウェア， インコーポレイテッド | 遺伝子変異を検出するためのシステム及び方法 |
| CN113643755B (zh) * | 2021-08-11 | 2023-10-13 | 上海小海龟科技有限公司 | 一种nipt试剂盒阳性率校正方法、装置、计算机设备和介质 |
| CN117095745B (zh) * | 2022-12-28 | 2025-12-12 | 安诺优达基因科技(北京)有限公司 | 用于检测孕妇血浆游离dna中胎儿非整倍体和拷贝数变异的方法和装置及应用 |
| SK289398B6 (sk) * | 2023-05-25 | 2026-01-14 | Medirex Group Academy N.O. | Metóda detekcie vzoriek s nedostatočným množstvom fragmentov fetálnej a cirkulujúcej nádorovej DNA na neinvazívne genetické testovanie |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016526879A (ja) | 2013-05-24 | 2016-09-08 | セクエノム， インコーポレイテッド | 遺伝子の変動の非侵襲性評価のための方法および処理 |
| JP2016533173A (ja) | 2013-06-21 | 2016-10-27 | セクエノム， インコーポレイテッド | 遺伝子の変動の非侵襲的評価のための方法および処理 |
| US20170275689A1 (en) | 2016-03-22 | 2017-09-28 | Counsyl, Inc. | Combinatorial DNA Screening |
| US20170316150A1 (en) | 2014-10-10 | 2017-11-02 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2615323A1 (en) | 2005-06-06 | 2007-12-21 | 454 Life Sciences Corporation | Paired end sequencing |
| US9163229B2 (en) | 2006-10-10 | 2015-10-20 | Trovagene, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
| US9029103B2 (en) | 2010-08-27 | 2015-05-12 | Illumina Cambridge Limited | Methods for sequencing polynucleotides |
| CN204440396U (zh) | 2012-04-12 | 2015-07-01 | 维里纳塔健康公司 | 用于确定胎儿分数的试剂盒 |
| WO2014151117A1 (en) * | 2013-03-15 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and use of circulating nucleic acid tumor markers |
| CN105830077B (zh) * | 2013-10-21 | 2019-07-09 | 维里纳塔健康公司 | 用于在确定拷贝数变异中改善检测的灵敏度的方法 |
| CA2945962C (en) | 2014-04-21 | 2023-08-29 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| AU2015367290A1 (en) | 2014-12-16 | 2017-05-11 | Garvan Institute Of Medical Research | Sequencing controls |
| HUE058263T2 (hu) | 2015-02-10 | 2022-07-28 | Univ Hong Kong Chinese | Mutációk detektálása rákszûrési és magzatelemzési célból |
| WO2017093561A1 (en) | 2015-12-04 | 2017-06-08 | Genesupport Sa | Method for non-invasive prenatal testing |
| US10095831B2 (en) | 2016-02-03 | 2018-10-09 | Verinata Health, Inc. | Using cell-free DNA fragment size to determine copy number variations |
| WO2018064486A1 (en) | 2016-09-29 | 2018-04-05 | Counsyl, Inc. | Noninvasive prenatal screening using dynamic iterative depth optimization |
| WO2019025004A1 (en) | 2017-08-04 | 2019-02-07 | Trisomytest, S.R.O. | METHOD FOR NON-INVASIVE PRENATAL DETECTION OF FETUS SEX CHROMOSOMAL ABNORMALITY AND FETUS SEX DETERMINATION FOR SINGLE PREGNANCY AND GEEMELLAR PREGNANCY |
| GB2615975B (en) * | 2019-02-14 | 2023-11-29 | Mirvie Inc | Methods and systems for determining a pregnancy-related state of a subject |
-
2020
- 2020-06-02 JP JP2021517942A patent/JP7506060B2/ja active Active
- 2020-06-02 KR KR1020217009511A patent/KR20220013349A/ko active Pending
- 2020-06-02 EP EP20747200.2A patent/EP3977459A1/en not_active Withdrawn
- 2020-06-02 AU AU2020286376A patent/AU2020286376A1/en not_active Abandoned
- 2020-06-02 CN CN202080005447.1A patent/CN112823391B/zh active Active
- 2020-06-02 US US17/281,565 patent/US12260935B2/en active Active
- 2020-06-02 CA CA3115513A patent/CA3115513A1/en active Pending
- 2020-06-02 WO PCT/US2020/035787 patent/WO2020247411A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016526879A (ja) | 2013-05-24 | 2016-09-08 | セクエノム， インコーポレイテッド | 遺伝子の変動の非侵襲性評価のための方法および処理 |
| JP2016533173A (ja) | 2013-06-21 | 2016-10-27 | セクエノム， インコーポレイテッド | 遺伝子の変動の非侵襲的評価のための方法および処理 |
| US20170316150A1 (en) | 2014-10-10 | 2017-11-02 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20170275689A1 (en) | 2016-03-22 | 2017-09-28 | Counsyl, Inc. | Combinatorial DNA Screening |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022534634A (ja) | 2022-08-03 |
| WO2020247411A1 (en) | 2020-12-10 |
| KR20220013349A (ko) | 2022-02-04 |
| CA3115513A1 (en) | 2020-12-10 |
| AU2020286376A1 (en) | 2021-04-22 |
| CN112823391B (zh) | 2024-07-05 |
| US20210366569A1 (en) | 2021-11-25 |
| EP3977459A1 (en) | 2022-04-06 |
| CN112823391A (zh) | 2021-05-18 |
| US12260935B2 (en) | 2025-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12087401B2 (en) | Using cell-free DNA fragment size to detect tumor-associated variant | |
| US12367978B2 (en) | Methods and systems for determining somatic mutation clonality | |
| JP6659672B2 (ja) | 胎児染色体部分異数性およびコピー数変動の検出 | |
| CN107077537B (zh) | 用短读测序数据检测重复扩增 | |
| AU2014281635B2 (en) | Method for determining copy number variations in sex chromosomes | |
| JP7009516B2 (ja) | 未知の遺伝子型の寄与体からのｄｎａ混合物の正確な計算による分解のための方法 | |
| JP7506060B2 (ja) | 検出限界ベースの品質管理メトリック | |
| US20220170010A1 (en) | System and method for detection of genetic alterations | |
| HK40047016B (zh) | 基於检测限的质量控制度量 | |
| HK40047016A (en) | Limit of detection based quality control metric | |
| HK40058694A (en) | Detecting repeat expansions with short read sequencing data | |
| HK40094109A (zh) | 用於检测遗传改变的系统和方法 | |
| HK40023955A (en) | Using cell-free dna fragment size to detect tumor-associated variant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221018 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230522 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20231208 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240528 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240529 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240613 |